secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001104659-26-028954
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports FY2025 results; deprioritizes lead drug zelenectide, plans 30% workforce cut
--------------------------------------------------------------------------------

- Deprioritizes zelenectide in mUC; converts Duravelo-2 to randomized Phase 2 after regulatory feedback says trial design no longer acceptable for approval.
- Proposes ~30% workforce reduction; expects 50% annual opex savings; cash runway extended into 2030.
- Appoints Jennifer Perry as COO; Alistair Milnes as CCDO. Perry receives $550K base salary, 50% bonus target.
- Cash $628.1M at Dec 31, 2025 vs $879.5M at Dec 31, 2024; FY2025 net loss $219M ($3.16/sh).
- Enters 15-year contract with UK Nuclear Decommissioning Authority for reprocessed uranium supply for radioconjugates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926028954/0001104659-26-028954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926028954/tm268887d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer